HeartFlow Inc

HeartFlow insider buying shows confidence amid volatility—executives buy below $9 while managing liquidity, hinting at a possible upside before Q4 earnings.

HeartFlow insider trades reveal major sell‑offs amid regulatory gains, showing how institutional moves and a 22% MACE‑reduction study may shape the stock’s next move.

HeartFlow’s recent Bain Capital sell‑off signals a strategic shift – 2 M shares sold, $56 M raised, yet market reaction stays muted as the company eyes R&D, partnerships, and future growth. This article explores the implications for investors and th…